Literature DB >> 25854154

[Therapeutic strategies for systemic lupus erythematosus].

M Schneider1.   

Abstract

Therapeutic strategy means the definition of a long-term target, which should be reached by a chosen management. As for rheumatoid arthritis, the treat to target initiative recommends remission as the target for systemic lupus erythematosus (SLE) but the command variables of remission are not yet defined. The basis of a therapeutic strategy is first the analysis of those factors that may influence the achievement of the objectives: SLE disease activity, the differentiation of damage, organ manifestations, comorbidities, genetics, sex, age of onset and considering the pathophysiological basis are some of these factors. The next step is the analysis of the available substances and concepts that allow the target to be reached. Finally, rules for management (e.g. guidelines) are needed that enrich the possibility to reach the target and improve the prognosis of patients suffering from SLE.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25854154     DOI: 10.1007/s00393-014-1457-1

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  20 in total

Review 1.  Anti-interferon alpha treatment in SLE.

Authors:  Kyriakos A Kirou; Elena Gkrouzman
Journal:  Clin Immunol       Date:  2013-03-01       Impact factor: 3.969

2.  Improvement of coping abilities in patients with systemic lupus erythematosus: a prospective study.

Authors:  M Haupt; S Millen; M Jänner; D Falagan; R Fischer-Betz; M Schneider
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

Review 3.  Cytokine inhibition as a strategy for treating systemic lupus erythematosus.

Authors:  Daniel N Clark; Jillian L Markham; Chad S Sloan; Brian D Poole
Journal:  Clin Immunol       Date:  2012-11-12       Impact factor: 3.969

4.  Accrual of organ damage over time in patients with systemic lupus erythematosus.

Authors:  Dafna D Gladman; Murray B Urowitz; Proton Rahman; Dominique Ibañez; Lai-Shan Tam
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

5.  Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus.

Authors:  Murray B Urowitz; Dafna D Gladman; Brian D M Tom; Dominique Ibañez; Vernon T Farewell
Journal:  J Rheumatol       Date:  2008-09-15       Impact factor: 4.666

6.  Understanding remission in real-world lupus patients across five European countries.

Authors:  M Schneider; M Mosca; J M Pego-Reigosa; E Hachulla; L-S Teh; A Perna; V Koscielny; J Pike; S Lobosco; G Apolone
Journal:  Lupus       Date:  2015-12-02       Impact factor: 2.911

7.  Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.

Authors:  Martin Aringer; Frederic Houssiau; Caroline Gordon; Winfried B Graninger; Reinhard E Voll; Eva Rath; Guenter Steiner; Josef S Smolen
Journal:  Rheumatology (Oxford)       Date:  2009-09-11       Impact factor: 7.580

8.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Authors:  G Bertsias; J P A Ioannidis; J Boletis; S Bombardieri; R Cervera; C Dostal; J Font; I M Gilboe; F Houssiau; T Huizinga; D Isenberg; C G M Kallenberg; M Khamashta; J C Piette; M Schneider; J Smolen; G Sturfelt; A Tincani; R van Vollenhoven; C Gordon; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2007-05-15       Impact factor: 19.103

9.  Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

Authors:  George K Bertsias; Maria Tektonidou; Zahir Amoura; Martin Aringer; Ingeborg Bajema; Jo H M Berden; John Boletis; Ricard Cervera; Thomas Dörner; Andrea Doria; Franco Ferrario; Jürgen Floege; Frederic A Houssiau; John P A Ioannidis; David A Isenberg; Cees G M Kallenberg; Liz Lightstone; Stephen D Marks; Alberto Martini; Gabriela Moroni; Irmgard Neumann; Manuel Praga; Matthias Schneider; Argyre Starra; Vladimir Tesar; Carlos Vasconcelos; Ronald F van Vollenhoven; Helena Zakharova; Marion Haubitz; Caroline Gordon; David Jayne; Dimitrios T Boumpas
Journal:  Ann Rheum Dis       Date:  2012-07-31       Impact factor: 19.103

10.  Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.

Authors:  Ian N Bruce; Aidan G O'Keeffe; Vern Farewell; John G Hanly; Susan Manzi; Li Su; Dafna D Gladman; Sang-Cheol Bae; Jorge Sanchez-Guerrero; Juanita Romero-Diaz; Caroline Gordon; Daniel J Wallace; Ann E Clarke; Sasha Bernatsky; Ellen M Ginzler; David A Isenberg; Anisur Rahman; Joan T Merrill; Graciela S Alarcón; Barri J Fessler; Paul R Fortin; Michelle Petri; Kristjan Steinsson; Mary Anne Dooley; Munther A Khamashta; Rosalind Ramsey-Goldman; Asad A Zoma; Gunnar K Sturfelt; Ola Nived; Cynthia Aranow; Meggan Mackay; Manuel Ramos-Casals; Ronald F van Vollenhoven; Kenneth C Kalunian; Guillermo Ruiz-Irastorza; Sam Lim; Diane L Kamen; Christine A Peschken; Murat Inanc; Murray B Urowitz
Journal:  Ann Rheum Dis       Date:  2014-05-16       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.